Welcome to our dedicated page for Translational Dev Acquisition SEC filings (Ticker: TDACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Dev Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Dev Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. reports its 2025 results as a blank check company focused on completing an initial business combination. It completed an IPO of 17,250,000 units at $10.00 each, plus 7,075,000 private placement warrants at $1.00, placing $174,225,000 into a trust at $10.10 per public share.
At December 31, 2025, investments in the trust totaled $181,657,311 and the company recorded net income of $6,362,427, driven by $7,306,965 of dividends on trust investments and $944,538 of operating costs. Cash outside the trust was $29,787 with a working capital deficit of $504,608.
The company has until June 24, 2026 to complete a business combination or redeem public shares and liquidate. Management discloses substantial doubt about its ability to continue as a going concern absent a timely deal or further sponsor support, while highlighting shareholder redemption protections and the sponsor’s limited indemnity for certain creditor claims.